The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism.
Tian LY, Smit DJ, Jücker M. · 2023
Read The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism. by Tian LY, Smit DJ, Jücker M. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9916527.txt.
Introduction
Tian and co-authors detail the PI3K/AKT/mTOR pathway in liver cancer metabolism. Hepatocellular carcinoma is a leading cause of cancer death worldwide. Tumors rewire metabolism, but that rewiring stays poorly mapped in this cancer. The named pathway is often disrupted in these tumors.
The review shows how the pathway controls glucose use in cancer cells. It also covers lipid, amino acid, pyrimidine, and oxidative metabolism. Each section links pathway signals to enzymes that tumors raise. The authors then summarize trials that test pathway blockers. Such drugs aim to cut the fuel supply of tumor cells. The work frames the pathway as a target for new liver cancer therapy.
Catalog record
| CREATOR | Tian LY, Smit DJ, Jücker M. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism By Ling-Yu Tian, Daniel J. Smit, Manfred Jücker, Stefania Cannito, Cristian Turato Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms24032652 ABSTRACT Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in the world. Metabolic reprogramming is considered a new hallmark of cancer, but it remains unclearly described in HCC. The dysregulation of the PI3K/AKT/mTOR signaling pathway is common in HCC and is, therefore, a topic of further research and the concern of developing a novel target for liver cancer therapy. In this review, we illustrate mechanisms by which this signaling network is accountable for regulating HCC cellular metabolism, including glucose metabolism, lipid metabolism, amino acid metabolism, pyrimidine metabolism, and oxidative metabolism, and summarize the ongoing clinical trials based on the inhibition of the PI3K/AKT/mTOR pathway in HCC. 1. INTRODUCTION Primary liver cancer (PLC) is one of the leading causes of cancer mortality worldwide, with around 841,000 new cases and 781,000 deaths every year. About 80% of all PLC are hepatocellular carcinomas (HCC), with increasing incidences over the past few years, making HCC the second leading cause of cancer death in East Asia and the sixth leading cause of cancer death in Western countries [1,2]. The main risk factors of HCC include hepatitis virus infection, auto-immune diseases, drug and non-drug related toxicity, as well as non-alcohol fatty liver disease (NAFLD) [3]. Increasing evidence demonstrates the close connection between metabolic factors, including metabolic syndrome, and the HCC prevalence in NAFLD patients [3]. Metabolic reprogramming is the significant metabolic phenotype of tumors [4,5]. Several metabolic enzymes, involved in glycolysis, lipogenesis, amino acid synthesis, and nucleotide biosynthesis, are augmented to reinforce the anabolic development of tumors in the process of metabolic reprogramming [6]. Malignant tumors can alter their metabolic pathways to sustain the high energy demand for uncontrolled growth and proliferation [7]. The Warburg effect is one of the most observed metabolic changes in malignancy that includes abnormally high glycolysis activity followed by lactate fermentation even in the presence of oxygen [8]. Oncogenic signaling transduction pathways, including the phosphoinositide 3-kinase (PI3K), AKT, and mammalian target of rapamycin (mTOR) pathways, enhance the Warburg effect in tumors, facilitating cancer cell growth and metastasis [9]. The liver plays an important role as a metabolic organ in the maintenance of body metabolic homeostasis and has crucial functions in regulating various metabolic pathways [10]. Cancer with activated PI3K/AKT signaling has been revealed to become more aggressive, and AKT pathway activation has been shown as a notable risk factor for earlier recurrence and poor prognosis in liver cancer patients [11]. Proteins of the PI3K/AKT/mTOR signaling pathway are significantly raised in PET/CT-positive HCC patients, indicating that activation of this pathway might be a key factor of the glycolytic phenotype in HCC cells [12]. Some mTOR inhibitors have been tested for treatment of HCC but have failed in clinical trials, and several new inhibitors on the PI3K/AKT/mTOR pathway are now in clinical trials for HCC patients [13]. However, the knowledge on the interplay of PI3K/AKT/mTOR signaling and its metabolic role in HCC is still limited. In this review, we highlight the role of the PI3K/AKT/mTOR pathway for the metabolism of HCC, with special emphasis on the molecular interactions. In addition, we offer an update on the ongoing clinical trials targeting the PI3K/AKT/mTOR pathway for HCC therapy. 2. THE PI3K/AKT/MTOR PATHWAY IN HCC The PI3K/AKT/mTOR signaling pathway regulates crucial cellular processes in the physiological setting as well as most hallmarks of cancer, including cell cycle, survival, metabolism, motility, and angiogenesis [14]. Dysregulation of the phosphatidylinositol 3-kinase (PI3K) is one of the most frequent events in tumorigenesis [15]. Currently, three classes of PI3K are known in the human genome, i.e., class I, class II, and class III [15]. The Class I PI3K are mainly known to drive tumorigenesis, and the activated Class I PI3K phosphorylates the phosphatidylinositol 4,5- biphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3) [16]. The Class I PI3Ks include four catalytic units encoded by PIK3CA, PIK3CB, PIK3CG, and PIK3CD [17]. In general, mutation of PI3K catalytic isoform p110α is the most common in human cancers, while the catalytic isoforms p110β, p110δ, and p110γ are rarely mutated but can be overexpressed in cancer [18]. PI3K is especially highly expressed in HCC tumor tissue, and the upregulation of PIK3CA was associated with HCC proliferation and negatively correlated with apoptosis. In addition, high expression of PIK3CA was associated with an unfavorable prognosis in HCC patients [19]. HCC patients with an early-stage recurrence have a higher mutation rate of PIK3CB [20]. Previous research demonstrated that certain microRNAs, including miR-142-3p, repress HCC progression and increase apoptosis to inhibit HCC by decreasing the PIK3CG-mediated activation of the PI3K/AKT pathway [21]. Regarding MiR-7, which targets PIK3C, it has been demonstrated that it controls cell proliferation and metastasis through the PI3K/AKT/mTOR pathway in HCC [22]. There are three Class II PI3K isoforms (PI3K-C2α, PI3K-C2β, and PI3K-C2γ) with different roles. PI3K-C2α plays a prominent role in endocytosis, vesicular trafficking, and mitosis; PI3K-C2β is related to cell migration and mTOR signaling repression and PI3K-C2γ regulates AKT2 activation and glycogen storage [23]. Downregulation of PI3KC2α leads to degraded vascular endothelial growth factor A (VEGFA)-mediated signaling and decreased angiogenesis in human HCC cells [24]. PI3K-C2β plays a crucial role in hepatitis C virus (HCV) propagation in human hepatocellular carcinoma cells [25]. Class III PI3K (i.e., PIK3C3) plays an essential role in cellular processes [26]. Inhibition of PIK3C3 blocks the activation of SGK3, which is the cancer stem cell (CSCs) promoter, and AMP-activated kinase (AMPK), thereby repressing the growth of HCC CSCs in mice [27]. The serine and threonine kinase AKT family includes three isoforms (i.e., AKT1, AKT2, and AKT3). A wide range of diseases, including cancer, is caused by AKT dysregulation [28]. In hepatocytes, expression of AKT1 as well as AKT2, but not AKT3, can be detected [29]. It has been demonstrated that c-MYC activation is strongly correlated with phosphorylated AKT1 expression and that HCC patients with relatively higher expression of AKT1, but not AKT2, have an unfavorable outcome [30]. However, previous research reported that AKT2 impacts the prognosis of HCC patients and that AKT2 may promote cell proliferation and invasion [31]. Furthermore, Galicia et al. reported that PI3K/AKT signaling is activated by loss of the tumor suppressor phosphatase and tensin homolog (PTEN) [32]. The preliminary role of AKT2 in the context of tumor transformation is not for the pro-survival or pro-growth of tumor cells; however, it displays the crucial function of metabolic regulation in the HCC model of mice [32]. The mammalian target of rapamycin (mTOR) kinase is a proficient regulator of protein synthesis that connects nutrient sensing to cell growth and is frequently observed in cancer [33]. The different proteins binding to mTOR activate their function by forming two complexes, which are called mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) [34]. Activation of PI3K and AKT leads to mTORC1 activation and phosphorylation of ribosomal protein S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E-binding protein-1 (4E-BP1). The mTORC2 complex includes the rapamycin-insensitive companion of mTOR (Rictor) and phosphorylates AKT, promoting AKT kinase activity [35]. Constitutive activation of PI3K/AKT/mTOR has been reported in cancer [36]. In 50% of